Results 71 to 80 of about 5,286 (232)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments

Advances in Rheumatology
Bruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase, plays a remarkable role in the transmission and amplification of extracellular signals to intracellular signaling pathways.
Gita Manzari Tavakoli, Niloufar Yazdanpanah, Nima Rezaei   +2 more
doaj   +1 more source

Ibrutinib‐induced severe liver injury

Clinical Case Reports, 2017
Key Clinical Message Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known.
Amara G. Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram   +7 more
doaj   +1 more source

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption

Bone Reports, 2019
Osteoclasts are responsible for bone erosion in osteoporosis and rheumatoid arthritis (RA). Both Btk and Tec kinases have essential functions in osteoclast differentiation.
Yuko Ariza, Masayuki Murata, Yoshiko Ueda, Toshio Yoshizawa   +3 more
doaj   +1 more source

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies

, 2018
Bruton's tyrosine kinase (BTK) is crucial in B-cell development and survival. The role of BTK as a downstream kinase in the B-cell receptor (BCR) signaling pathway is well described.
da Cunha-Bang, Caspar, Niemann, Carsten Utoft   +1 more
core   +1 more source

Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation [PDF]

, 2018
Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and ...
Sara V. Merino-Cortes, Rudi W. Hendriks, Yolanda R. Carrasco, Marjolein J. W. de Bruijn, Sofia R. Gardeta, Sara Roman-Garcia   +5 more
core   +2 more sources

Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis

Arthritis Research & Therapy, 2023
Background Bruton’s tyrosine kinase (Btk) is an enzyme expressed in leukocytes other than T lymphocytes and plasma cells and involved in B-cell receptor- and Fcγ receptor (FcγR)-mediated signal transduction.
Issei Nakade, Yuto Tamura, Fuyu Hashimoto, Yuko Ariza, Shingo Hotta, Hirofumi Fujigaya, Suishin Arai, Mai Taniguchi, Hodaka Ogawa, Yuka Nishibata, Sakiko Masuda, Daigo Nakazawa, Utano Tomaru, Akihiro Ishizu   +13 more
doaj   +1 more source

BTK (Bruton agammaglobulinemia tyrosine kinase) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on BTK (Bruton agammaglobulinemia tyrosine kinase), with data on DNA, on the protein encoded, and where the gene is implicated.
Hendriks, RW, van, Loo PF
openaire   +2 more sources

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source